Caris Molecular Intelligence tumour profiling services help to individualise treatment selection for cancer patients
Caris Molecular Intelligence™ is an evidence-guided tumour profiling service, which aims to help physicians select the best available therapy for each patient. It examines a broad range of established biomarkers using the best available technologies and with the help of a proprietary database, associates drugs that are more or less likely to benefit each individual patient. Using the MI Profile™ report, physicians are able to more easily translate the results from published clinical studies into individualised treatment plans.
Since 2005, Caris Molecular Intelligence has helped more than 6,000 physicians in 58 countries worldwide, to manage therapeutic dilemmas for over 60,000 cancer patients with 150 different histology subtypes.
Read here about which patients are most suitable for tumour profiling, the Molecular Intelligence process and available profiling options.
Download a sample report to learn more about how Caris Molecular Intelligence results can help to inform treatment decisions.
For further details about sample requirements, laboratory processes, reimbursement and evidence proving the utility of molecular profiling, contact us.
Frequently asked questions:
What are the potential clinical benefits of Caris Molecular Intelligence?
Molecular Intelligence helps to build an individualised treatment plan when therapeutic ambiguities exist in patients with unresectable primary tumours or metastatic disease.
Caris Molecular Intelligence allows physicians to:
• Navigate among therapies with potential benefit
• Identify therapies which may not have been considered
• Determine drugs with potential lack of benefit